Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Research & Development: 2022-2024

Historic Research & Development for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $125.3 million.

  • Entrada Therapeutics' Research & Development rose 22.73% to $38.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.7 million, marking a year-over-year increase of 17.91%. This contributed to the annual value of $125.3 million for FY2024, which is 25.45% up from last year.
  • Entrada Therapeutics' Research & Development amounted to $125.3 million in FY2024, which was up 25.45% from $99.9 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Research & Development registered a high of $125.3 million during FY2024, and its lowest value of $66.6 million during FY2022.
  • For the 3-year period, Entrada Therapeutics' Research & Development averaged around $97.3 million, with its median value being $99.9 million (2023).
  • Data for Entrada Therapeutics' Research & Development shows a peak YoY spiked of 49.96% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Entrada Therapeutics' Research & Development stood at $66.6 million in 2022, then skyrocketed by 49.96% to $99.9 million in 2023, then grew by 25.45% to $125.3 million in 2024.